Dyadic Pivots to Larger Strategic Partnerships
The biotech company says it will rely on external partners with capital and distribution networks to scale its protein production platforms.
Updated on Nov. 13, 2026 in Biotech

Dyadic announced on its third-quarter 2026 earnings call that it will pursue larger strategic partnerships to scale its protein production platforms. Partner Inzymes made its first commercial sale of camel chymosin in October 2026.
Why it matters
Dyadic lacks the capital to fund independent manufacturing, so external licensing deals are the primary driver of its future revenue. Its direct commercial sales remain modest, making partner-led scaling central to converting platform validation into recurring income.
The figures are company-reported fermentation yields from Dyadic's C1 platform, supported by roughly $3.1 million in Gates-funded grants for antibody testing. How quickly partners will convert these results into commercial volumes has not been disclosed.
The players
Dyadic
Dyadic is a biotechnology company that develops protein production platforms and licenses them to partners for commercial scaling.
Inzymes
Inzymes is a company that has partnered with Dyadic and made the first commercial sale of camel chymosin in October 2026.
The details
On its November 12, 2026 earnings call, Dyadic said it would favor licensing its production systems to established partners that already own manufacturing and distribution networks over funding stand-alone manufacturing infrastructure. The company cited the first commercial sale of camel chymosin by partner Inzymes in October 2026 as an example of its model in practice.
Timeline
October 2026: Partner Inzymes makes its first commercial sale of camel chymosin.
November 12, 2026: Dyadic holds its third-quarter 2026 earnings call and announces the shift toward larger strategic partnerships.
Platform Pivot
The move follows Dyadic's C1 platform validation, shifting the company from developing production capacity itself toward licensing C1 to partners that can fund manufacturing. Additional C1 validation remains necessary before the platform reaches broad commercial use.
For readers following protein and antibody therapies, the shift means that new production capacity will depend on partners like Inzymes rather than on Dyadic itself. Commercial availability of C1-produced products will therefore hinge on those partnerships converting into scaled manufacturing.
The takeaway
Platform companies with limited capital often scale by licensing their technology to partners with manufacturing and distribution networks. Watching which partnerships Dyadic signs next will show whether that model is gaining traction.
Further reading
For more on how biotech firms are scaling production, see Biotech.
Source note: This article includes information reported by The Motley Fool.







